Approval · Notice of Compliance 4323 · 1996
NIMBEX: Notice of Compliance 4323
Issued December 18, 1996
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 4323
- Date
- December 18, 1996
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Non-depolarizing skeletal neuromuscular blocking agent
Products in this notice
Medicinal ingredients
- CISATRACURIUM BESYLATE 2 MG per ML
- CISATRACURIUM BESYLATE 10 MG per ML